Filtered By:
Drug: Pradaxa
Management: Hospitals
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 42 results found since Jan 2013.
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
Publication date: 9–15 June 2018 Source:The Lancet, Volume 391, Issue 10137 Author(s): P J Devereaux, Emmanuelle Duceppe, Gordon Guyatt, Vikas Tandon, Reitze Rodseth, Bruce M Biccard, Denis Xavier, Wojciech Szczeklik, Christian S Meyhoff, Jessica Vincent, Maria Grazia Franzosi, Sadeesh K Srinathan, Jason Erb, Patrick Magloire, John Neary, Mangala Rao, Prashant V Rahate, Navneet K Chaudhry, Bongani Mayosi, Miriam de Nadal, Pilar Paniagua Iglesias, Otavio Berwanger, Juan Carlos Villar, Fernando Botto, John W Eikelboom, Daniel I Sessler, Clive Kearon, Shirley Pettit, Mukul Sharma, Stuart J Connolly, Shrikant I Bangdiwala, ...
Source: The Lancet - June 8, 2018 Category: General Medicine Source Type: research
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood
AbstractDabigatran etexilate is an oral direct thrombin (Factor IIa) inhibitor approved for patients with atrial fibrillation and for management of risk of deep vein thrombosis and pulmonary embolism. Dabigatran offers advantages over treatment with warfarin, including limited laboratory monitoring. It is equivalent in prevention of stroke and deep vein thrombosis with essentially equivalent complication rates. In contrast to warfarin, reversal of the anticoagulation is less well established. Idarucizumab is available for reversal, however supporting research is mixed; the agent also happens to be quite expensive making av...
Source: Indian Journal of Hematology and Blood Transfusion - June 21, 2020 Category: Hematology Source Type: research
Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation
The objective was to determine the rates of inappropriate inpatient DOAC dosing in AF and identifying its associated underlying factors. We conducted a retrospective cross-sectional study from December 2013 to November 2019 across six South Australian public hospitals utilising a centralised electronic health record. Multivariate analysis was used to identify factors associated with underdosing of patients prescribed apixaban. Of 1882 inpatients, 544 (28.9 %) were inappropriately dosed. Underdosing was the most common form of inappropriate dosing with rates of 22.9 % (n = 295), 7.1 % (n = 7), and 25.1 % (n...
Source: Journal of Thrombosis and Thrombolysis - July 24, 2021 Category: Hematology Source Type: research
Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity
Clin Ther. 2021 Aug 5:S0149-2918(21)00247-2. doi: 10.1016/j.clinthera.2021.07.003. Online ahead of print.ABSTRACTPURPOSE: Direct oral anticoagulants (DOACs) are recommended in preference to vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) eligible for oral anticoagulation therapy; however, data and clinical experiences supporting the use of DOACs in patients with a body mass index ≥40 kg/m2 or weight >120 kg remain limited. The aim of this study was to evaluate the pharmacokinetic properties of DOACs in patients with AF and extreme obesity.METHODS: We enrolled all consecutiv...
Source: Clinical Therapeutics - August 9, 2021 Category: Drugs & Pharmacology Authors: Vincenzo Russo Dario Cattaneo Laura Giannetti Roberta Bottino Nunzia Laezza Umberto Atripaldi Emilio Clementi Source Type: research
DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes
This article is protected by copyright. All rights reserved.PMID:37178305 | DOI:10.1002/jcph.2283
Source: The Journal of Clinical Pharmacology - May 13, 2023 Category: Drugs & Pharmacology Authors: Nauka J Bhalodia Jesse Cheng Connor R Deri Kelsey Stahl Heather Heiney Olivia Marchionda Carlo J Iasella James C Coons Source Type: research
Direct oral anticoagulants: patient reported adherence and minor bleedings
AbstractData regarding adherence and minor bleeding on direct oral anticoagulants in everyday life are still sparse. Inclusion criteria: treatment initiated with dabigatran, rivaroxaban or apixaban in non-valvular atrial fibrillation patients from a center in northern Sweden between 2011 and 2019 (n = 668). Exclusion criteria: cognitive impairment, dose dispensing, need of interpreter or hospital admission (n = 67). By a telephone interview adherence was measured in 569 patients (response rate 94.8%) using the 8-item Morisky medication adherence scale and minor bleeding was asked for. CHA2DS2-VASc and HAS-BLED sco...
Source: Journal of Thrombosis and Thrombolysis - June 22, 2023 Category: Hematology Source Type: research
Outcomes Following Bleeding on Direct Oral Anticoagulants in Patients With Atrial Fibrillation at Liverpool Hospital
Direct oral anticoagulants (DOACs) are vital in atrial fibrillation (AF) stroke prevention. On-treatment bleeding has significant morbidity and mortality. Dabigatran is reversible with an available specific agent; however, the Factor-Xa-Inhibitor (FxaI) reversal-agent has limited availability.
Source: Heart, Lung and Circulation - July 1, 2023 Category: Cardiology Authors: Z. Wang, D. Nguyen, P. Motum, D. Hsu, S. Ng, S. Lo Source Type: research
